Senaparib
As of the edition of 20 October 2026, Senaparib is a small molecule: in active development; acts on PARP1 and PARP2.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Active, 2025
- Kind
- Small molecule
- Registered trials
- 15, 1 stopped early
- Disease areas
- Cancer; Hormones; Pregnancy and women's health; Urinary and reproductive; Skin and connective tissue; Lungs and airways
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Targets
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase not stated | 1 | 0 | 1 | 0 |
| Phase 1 | 10 | 9 | 0 | 1 |
| Phase 2 | 4 | 2 | 2 | 0 |
| All trials | 15 |
Who ran its trials
| Company | Role | Years |
|---|---|---|
| Impact Therapeutics | Lead sponsor of trials | 2017 to now |
| Junshi Bioscience | Lead sponsor of trials | 2022 to now |